BiondVax – executive interview

Published on 25 May 2021

In this interview, Amir Reichman, BiondVax’s new CEO, discusses why he left GSK Vaccines after many years of senior leadership positions to lead BiondVax, a small biopharmaceutical company in Israel. He also discusses his short-term goals and long-term vision for the company.

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and, ultimately, commercialising products for the prevention and treatment of infectious diseases and related illnesses. The company had been developing M‑001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future seasonal and pandemic influenza. In seven Phase I/II and Phase II clinical trials designed to test for immunogenicity, the company was able to demonstrate that M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, BiondVax completed a Phase III clinical trial of M‑001 that failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space towards developing a pipeline of diversified products and platforms.

Share this with friends and colleagues